dgkh000530
10.3205/dgkh000530
urn:nbn:de:0183-dgkh0005307
Research Article
Bactericidal and virucidal action of cetylpyridinium chloride and benzocaine lozenges against common oropharyngeal pathogens
Bakterizide und viruzide Wirkung von Cetylpyridiniumchlorid-haltigen Lutschtabletten gegen typische oropharyngeale Erreger
Peiter
Peiter
Tina
T
Reckitt Benckiser Deutschland GmbH, Darwinstraße 2–4, 69115 Heidelberg, Germany; phone: +49 160 745 1132Reckitt Benckiser Deutschland GmbH, Heidelberg, Germany
tina.Peiter@reckitt.com
author
de Grey-Warter
de Grey-Warter
Fergus
F
Reckitt Benckiser Healthcare Ltd, Hull, United Kingdom
author
Stahl
Stahl
Tessa
T
Reckitt Benckiser Deutschland GmbH, Heidelberg, Germany
author
Hallet
Hallet
Thomas
T
Reckitt Benckiser Healthcare Ltd, Hull, United Kingdom
author
Matthews
Matthews
Derek
D
Reckitt Benckiser Healthcare Ltd, Slough, United Kingdom
author
Eggers
Eggers
Maren
M
Labor Prof. Gisela Enders MVZ GbR, Stuttgart, Germany
author
German Medical Science GMS Publishing House
Düsseldorf
610
antibacterial agent
virucidal agent
antiseptic agent
drug resistance
benzocaine
cetylpyridinium
lozenges
pharyngitis
bovine coronavirus
influenza virus A
Bakterizid
virucid
Antiseptikum
Antibiotikaresistenz
Benzocain
Cetylpyridinium
Lutschtablette
Pharyngitis
bovines Coronavirus
Influenza virus A
20250224
engl
This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 License.
Dieser Artikel ist ein Open-Access-Artikel und steht unter den Lizenzbedingungen der Creative Commons Attribution 4.0 License (Namensnennung).
2196-5226
20
GMS Hygiene and Infection Control
GMS Hyg Infect Control
01
20250505Spelling correction
Zielsetzung: Bei der Behandlung von Pharyngitis werden Antibiotika zu häufig verschrieben, was zu antimikrobiellen Resistenzen beitragen kann. In der vorliegenden Arbeit wurden die antiviralen und antibakteriellen Eigenschaften von zuckerfreien Lutschtabletten mit Cetylpyridiniumchlorid (CPC) und Benzocain in vitro untersucht. Das stellt möglicherweise eine geeignetere Behandlung für typische Pharyngitiden dar. Methode: Die antiviralen Eigenschaften von zuckerfreien CPC/Benzocain (1,4 mg/10 mg) Lutschtabletten (Dolo-Dobendan 1,4 mg/10 mutschtabletten) wurden im Suspensionstest nach DIN EN 14476:2019-10 gegen das bovine Coronavirus (S379 Reims) und das Influenzavirus A (H1N1/Brisbane/59/2007) unter hoher und niedriger Belastung untersucht. Die Virustiter wurden nach 1, 5, 10 und 30 min Kontaktzeit gemessen und eine Reduktion von ≥4 lg wurde als viruzid angesehen. Für das bovine Coronavirus wurde zur Reduzierung der Zytotoxizität das Large-Volume-Plating-Verfahren angewendet. Die antimikrobiellen Eigenschaften wurden gegenüber 11 Mikroorganismen, die mit Pharyngitis assoziiert sind, gemessen. Die Kontaktzeiten waren 1, 5 und 10 min (+30 min für die Positivkontrolle). Ergebnisse: Gegenüber dem Influenzavirus zeigten die Lutschtabletten eine Reduktion von ≥4 lg nach 5 bzw. 10 min sowohl unter niedriger als auch unter hoher Belastung. Die Lutschtabletten zeigten gegenüber dem bovinen Coronavirus unter beiden Bedingungen eine Reduktion von ≥4 lg nach 10 min. Eine bakterizide Wirkung wurde innerhalb von 5 min gegen neun der Mikroorganismen beobachtet, mit <10 koloniebildenden Einheiten (KBE)/mL für Pseudomonas aeruginosa, Staphylococcus aureus, Arcanobacterium haemolyticum, Moraxella catarrhalis, Porphyromonas gingivalis, Prevotelia intermedia, Streptococcus dysgalactiae und Streptococcus pyogenes und <100 KBE/mL für Streptococcus pneumoniae. Candida albicans und Escherichia coli wiesen nach 30 min Werte von <10 KBE/mL auf. Schlussfolgerung: CPC/Benzocain (1,4 mg/10 mg) Lutschtabletten können bei unkomplizierter Pharyngitis empfohlen werden und bieten möglicherweise eine gute Alternative bei nicht zielführender Antibiose und können somit helfen, antimikrobielle Resistenzen einzudämmen.
Aim: Too often, antibiotics are prescribed in the treatment of pharyngitis, which can contribute to antimicrobial resistance. We aimed to assess the in vitro antiviral and antimicrobial activity of sugar-free cetylpyridinium chloride (CPC)/benzocaine lozenges, which can potentially offer a more suitable treatment for pharyngitis. Methods: The antiviral activity of sugar-free CPC/benzocaine (1.<![CDATA[4 m</PlainText></TextGroup>g/1<TextGroup><PlainText>0 m</PlainText></TextGroup>g) lozenges (Dolo-Dobendan 1.4 mg/10 mg lozenges) was assessed using the DIN EN 14476:2019–10 suspension test against bovine coronavirus (S379 Reims) or influenza virus A (H1N1/Brisbane/59/2007) under clean and dirty conditions. Viral titers were measured after 1, 5, 10, and 30 min exposure; a reduction of <TextGroup><PlainText>≥4 lg</PlainText></TextGroup> was considered virucidal. For bovine coronavirus, large volume plating was used due to cytotoxicity. Antimicrobial activity was measured against 11 microorganisms associated with pharyngitis, with contact times of 1, 5, and 10 min (+30 min for positive control). </Pgraph><Pgraph><Mark1>Results:</Mark1> For influenza, sugar-free lozenges showed ≥4 lg efficacy from 5 and 10 min exposure under clean and dirty conditions, respectively. For bovine coronavirus, sugar-free lozenges exhibited ≥4 lg efficacy at 10 min under both conditions. Bactericidal activity was observed against nine of the challenge microorganisms within 5 min, with plate counts of <10 colony-forming units (CFU)/mL for <Mark2>Pseudomonas aeruginosa</Mark2>, <Mark2>Staphylococcus aureus</Mark2>, <Mark2>Arcanobacterium haemolyticum</Mark2>, <Mark2>Moraxella catarrhalis</Mark2>, <Mark2>Porphyromonas gingivalis</Mark2>, <Mark2>Prevotelia intermedia</Mark2>, <Mark2>Streptococcus dysgalactiae</Mark2>, and <Mark2>Streptococcus pyogenes</Mark2>, and <100 CFU/mL for <Mark2>Streptococcus pneumoniae. Candida albicans and Escherichia coli</Mark2> showed counts of <10 CFU/mL at 30 min. </Pgraph><Pgraph><Mark1>Conclusions:</Mark1> Sugar-free CPC/benzocaine lozenges can be recommended for uncomplicated pharyngitis and may be more appropriate than antibiotics, helping to mitigate antimicrobial resistance. </Pgraph></Abstract>
<TextBlock name="Introduction" linked="yes">
<MainHeadline>Introduction</MainHeadline><Pgraph>The cold and flu season occurs mainly during the winter months in temperate climates, and in tropical regions there are irregular outbreaks throughout the year <TextLink reference="1"></TextLink>, <TextLink reference="2"></TextLink>. However, since the COVID-19 pandemic, the timing and duration of flu seasons have become less predictable <TextLink reference="3"></TextLink>. Acute pharyngitis (sore throat) is a typical symptom of upper respiratory tract infections (URTIs) and one of the most common reasons for seeking medical care globally <TextLink reference="4"></TextLink>, <TextLink reference="5"></TextLink>. For example, in Germany, pharyngitis accounts for 2.7% of all primary care consultations <TextLink reference="6"></TextLink>. </Pgraph><Pgraph>The most frequent cause of pharyngitis is a viral infection, responsible for around 80% of adult cases <TextLink reference="5"></TextLink>, <TextLink reference="7"></TextLink>, <TextLink reference="8"></TextLink>, <TextLink reference="9"></TextLink>. Some of the most common enveloped viruses implicated in the etiology of pharyngitis are coronaviruses, ortho- and paramyxoviruses (e.g., influenza viruses) <TextLink reference="10"></TextLink>. A number of bacterial species can also be responsible for pharyngitis, but<Mark2> Streptococcus (S.) pyogenes</Mark2> (also known as group A β-hemolytic <Mark2>Streptococcus</Mark2> [GABHS]) is the most common bacterial cause of pharyngitis <TextLink reference="8"></TextLink>, <TextLink reference="9"></TextLink>. Antibiotics are prescribed in most cases of pharyngitis, despite the fact that the majority of cases are caused by viral infections, and antibiotics are ineffective against viruses <TextLink reference="5"></TextLink>, <TextLink reference="7"></TextLink>, <TextLink reference="8"></TextLink>, <TextLink reference="9"></TextLink>. Most cases of pharyngitis are self-limiting, regardless of the etiology <TextLink reference="11"></TextLink>, and improve without the need for antibiotics <TextLink reference="9"></TextLink>. Inappropriate antibiotic usage for self-limiting conditions, such as pharyngitis, contributes to antimicrobial resistance, which is a global health threat <TextLink reference="11"></TextLink>, <TextLink reference="12"></TextLink>. There is a need for non-antibiotic treatments, such as topical formulations that have antimicrobial and pain-relieving qualities, so that antibiotics can be reserved for bacterial pharyngitis and patients with an increased risk of complications <TextLink reference="7"></TextLink>, <TextLink reference="8"></TextLink>. In general, topical formulations are less likely to cause antimicrobial resistance than systemic antibiotics and have been proven to reliably deliver antiseptically active substances to the throat mucosa <TextLink reference="13"></TextLink>, <TextLink reference="14"></TextLink>. </Pgraph><Pgraph>Over-the-counter (OTC) medicated throat lozenges containing antiseptics and anesthetics are one option for the symptomatic relief of sore throat. Some have proven efficacy and provide immediate release of active ingredients directly at the site of infection, which offers rapid symptomatic relief <TextLink reference="7"></TextLink>, <TextLink reference="8"></TextLink>, <TextLink reference="15"></TextLink>, <TextLink reference="16"></TextLink>, <TextLink reference="17"></TextLink>. Cetylpyridinium chloride (CPC) is an antiseptic found in throat lozenges that has been described as a successful bactericide against gram-positive and, in higher concentrations, some gram-negative bacteria <TextLink reference="10"></TextLink>, <TextLink reference="17"></TextLink>. CPC also has variable antifungal activity, and some studies suggest its efficacy against certain enveloped viruses <TextLink reference="10"></TextLink>, <TextLink reference="17"></TextLink>. Anesthetics provide symptomatic pain relief and are often combined with antiseptics in throat lozenge formulations <TextLink reference="17"></TextLink>. Lozenges containing CPC and benzocaine are well established for the symptomatic relief of sore throat and have a favorable safety profile. These medicated lozenges have been available OTC for several decades in certain countries <TextLink reference="10"></TextLink>, <TextLink reference="18"></TextLink>. However, the virucidal and antimicrobial effects of these lozenges have not been widely reported to date. Using CPC mouthrinse at a concentration of 0.05% results in an immediate reduction in bacterial counts by 2.0 to 2.5 lg steps. The effect reverts to about 1 lg step after 1 hour <TextLink reference="19"></TextLink>. CPC is virucidal against both susceptible and resistant strains of influenza viruses at concentrations between 5.0 and 12.5 µg/mL without leading to the development of resistance, and it also reduces influenza-associated mortality and morbidity <TextLink reference="20"></TextLink>.</Pgraph><Pgraph>As a result of the COVID-19 pandemic, the use of antiseptics considerably increased due to their antiviral properties against SARS-CoV-2 <TextLink reference="21"></TextLink>. There is a need for robust antiviral data that are applicable to the clinical situation. The European tiered approach on the virucidal standard, EN 14476, helps provide recommendations regarding the choice of antiseptics that can be used with proven virucidal efficacy <TextLink reference="22"></TextLink>. Viral infections are associated with an increased incidence or severity of bacterial co-infections, which may contribute to severe disease <TextLink reference="23"></TextLink>, <TextLink reference="24"></TextLink>. Therefore, combining antiviral and antimicrobial properties in OTC treatments may possibly prevent potential co-infections and improve outcomes. This study assessed the in vitro antimicrobial and antiviral activities of sugar-free CPC/benzocaine lozenges against pathogens known to cause pharyngitis. </Pgraph></TextBlock>
<TextBlock name="Materials and methods" linked="yes">
<MainHeadline>Materials and methods</MainHeadline><SubHeadline>Antiviral method</SubHeadline><SubHeadline2>Antiviral test</SubHeadline2><Pgraph>CPC 1.4 mg/benzocaine 10 mg sugar-free lozenges (Dolo-Dobendan<Superscript>®</Superscript>, Reckitt Benckiser Deutschland GmbH, Heidelberg, Germany) were dissolved in 6 mL of distilled water (per lozenge) to make a final concentration of 80%. </Pgraph><Pgraph>The test sample was prepared according to DIN EN 14476:2019-10 (phase 2/step 1). The sugar-free test samples were added to a suspension of influenza virus A/H1N1/Brisbane/59/2007 or bovine coronavirus strain ‘S379 Riems’ and an interfering substance, which consisted of clean conditions with 0.3 g/L bovine serum albumin (BSA) or a tripartite soil load according to the Organisation for Economic Co-operation and Development (OECD) with 5% BSA fraction V, 5% yeast extract, 0.4% mucosal protein mucin. The test temperature used was 20°C±1°C, which corresponds to the ‘worst case’ test condition according to the EN 14476 standard. The contact times were 1, 5, 10, and 30 min. At the end of each contact time, 0.5 mL of the test sample was immediately diluted in 4.5 mL of an ice-cold maintenance medium to suppress the virucidal action of the test sample. Ten-fold dilutions of the maintenance medium and test sample mixture were transferred onto Madin-Darby canine kidney (MDCK) and <Mark2>Ovis aries</Mark2> (CCLV-Rie11) cells in 96-well microtiter plates for influenza and bovine coronavirus, respectively. After incubation at 37°C±1°C in a humidified atmosphere under 5.0% CO<Subscript>2</Subscript>, the plates were observed for viral cytopathic effect (CPE), and titers of viral infectivity were calculated using the Spearman and Kärber method (lg 50% tissue culture infectious dose [TCID<Subscript>50</Subscript>]/mL with 95% confidence interval). Reduction of virus infectivity was calculated using the differences of lg virus titer with the control (without test lozenge) and after treatment with the lozenge. A reduction of ≥4 lg was considered virucidal. In cases of cytotoxicity in the test samples against bovine coronavirus, a large-volume plating (LVP) method was carried out by inoculating the total volume from the first non-cytotoxic dilution. </Pgraph><SubHeadline>Antimicrobial method</SubHeadline><SubHeadline2>Antimicrobial activity test</SubHeadline2><Pgraph>CPC 1.4 mg/benzocaine 10 mg sugar-free lozenges (Dolo-Dobendan<Superscript>®</Superscript>, Reckitt Benckiser Deutschland GmbH, Heidelberg, Germany) were dissolved at 42–44°C in <TextGroup><PlainText>5 m</PlainText></TextGroup>L of artificial saliva medium (ARTS), which contains 0.1% meat extract (Sigma 70164), 0.2% yeast extract (LP0021), 0.5% proteose peptone (LP0085), 0.02% potassium chloride (Fisher P/4240), 0.02% sodium chloride (Sigma S7653), 0.03% calcium carbonate (Fisher C/1040), 0.2% glucose (Fisher G/0450), and 0.2% mucin from porcine stomach, type 2 (Sigma M2378), per lozenge. Three test samples were prepared for each challenge microorganism. </Pgraph><Pgraph>Each CPC/benzocaine test sample (4.9 mL) and positive control (4.9 mL of ARTS) were inoculated with 100 µL of the appropriate challenge microorganisms outlined in Table 1 <ImgLink imgNo="1" imgType="table" />, to provide an inoculum level of >1.0x10<Superscript>4</Superscript> colony-forming units (CFU)/mL. The solution was mixed thoroughly using a vortex mixer and incubated at 36–38°C. Inoculum suspensions were prepared in triplicate for each of the 11 challenge microorganisms. Antimicrobial activity was measured after 1-, 5-, 10- and 30-min contact times (30 min only for the positive control) by removing 1 mL of the test sample and placing it into 9 mL of neutralizing diluent with 0.1% peptone water, 1% tween 80, 0.3% lecithin, and sodium chloride (PTLS). Solutions were serially diluted to 10<Superscript>–5</Superscript> and incubated on appropriate nutrient agar medium for at least 3 days (Table 1 <ImgLink imgNo="1" imgType="table" />). Antimicrobial activity (in CFU/mL) was calculated for each challenge microorganism and time point (average of three replicates). </Pgraph><SubHeadline>Method suitability testing</SubHeadline><Pgraph>The test was performed in a manner similar to that of the antimicrobial activity test, with minor differences (<TextGroup><PlainText>Table 2 </PlainText></TextGroup><ImgLink imgNo="2" imgType="table" />). The method suitability test was carried out to verify that any antimicrobial activity in the sample was effectively neutralized. </Pgraph></TextBlock>
<TextBlock name="Results" linked="yes">
<MainHeadline>Results</MainHeadline><SubHeadline>Virucidal efficacy</SubHeadline><SubHeadline2>Influenza virus</SubHeadline2><Pgraph>Sugar-free lozenges exhibited a virucidal efficacy of <TextGroup><PlainText>≥4 lg</PlainText></TextGroup> from 5 and 10 min onwards under clean conditions and with a tripartite soil load, respectively (Table 3 <ImgLink imgNo="3" imgType="table" />). </Pgraph><SubHeadline2>Bovine coronavirus and cytotoxic effect</SubHeadline2><Pgraph>Cytotoxicity (deformation of cells and destruction of cell monolayer) made it impossible to achieve the required 4 lg reduction against bovine coronavirus and was detected in the test samples. Therefore, to be able to detect a titer reduction of over 4 lg levels, the LVP method was carried out. Sugar-free lozenges tested against bovine coronavirus showed a virucidal efficacy of 2.67 lg reduction under clean conditions and a 3.4 lg reduction with a tripartite soil load at the 5-min time point. Sufficient virucidal efficacy was also demonstrated at the 10-min time point: ≥3.0 lg reduction under clean conditions and 4.06 lg reduction with a tripartite soil load (Table 4 <ImgLink imgNo="4" imgType="table" />). </Pgraph><SubHeadline>Microbicidal efficacy</SubHeadline><SubHeadline2>Validity of neutralization</SubHeadline2><Pgraph>For all microorganisms, except <Mark2>S. pneumoniae</Mark2>, the counts for the 10<Superscript>–1</Superscript> dilution test result (10<Superscript>–2</Superscript> dilution with <TextGroup><Mark2>S. pn</Mark2></TextGroup><Mark2>eumoniae</Mark2>) did not vary by more than a factor of two from the peptone control result. This suggests that any antimicrobial activity present had been sufficiently removed at this dilution and that the method was suitable. The method suitability test was valid because the inoculum levels of each of the microorganism species were 10–150 CFU and there was no growth in any of the negative controls. </Pgraph><SubHeadline2>In vitro antimicrobial activity of CPC/benzocaine sugar-free lozenges</SubHeadline2><Pgraph><Mark2>S. aureus</Mark2> and <Mark2>S. pyogenes</Mark2> showed counts of <10 CFU/mL at the 5-min time point onwards, whereas <Mark2>C. albicans</Mark2> and <Mark2>E. coli</Mark2> showed counts of <10 CFU/mL at the 30-min timepoint for all replicates. <Mark2>S. pneumoniae</Mark2> showed counts of <100 CFU/mL at the 1-min time point onwards for all replicates. A total of six bacterial species showed counts of <10 CFU/mL at the 1-min time point onwards for all replicates (<Mark2>A. haemolyticum, M. catarrhalis, P. gingivalis, P. intermedia, P. aeruginosa, S. dysgalactiae</Mark2>; Table 5 <ImgLink imgNo="5" imgType="table" />). </Pgraph></TextBlock>
<TextBlock name="Discussion" linked="yes">
<MainHeadline>Discussion</MainHeadline><Pgraph>OTC antiseptic/anesthetic lozenges are helpful in the management of sore throat, offering easy access to symptomatic relief and providing a more suitable alternative treatment to antibiotics, which contribute to antimicrobial resistance <TextLink reference="9"></TextLink>, <TextLink reference="18"></TextLink>. Most upper respiratory tract infections are self-limiting and do not require antibiotics; therefore, if more patients are encouraged to use self-management options, it could help reduce the inappropriate use of antibiotics <TextLink reference="25"></TextLink>. Generating robust in vitro data is essential to understand the efficacy of antiseptics so that they can be presented as a valid alternative to primary-care visits. Antiseptic lozenges are widely available for the treatment of pharyngitis <TextLink reference="26"></TextLink>, and having a better understanding of their efficacy can support the recommendation of these treatments at the appropriate place in the care pathway, and also differentiate them from non-medicated, purely demulcent throat sweets or moisturizing medicinal devices. CPC/benzocaine is a well-established treatment for pharyngitis <TextLink reference="18"></TextLink>; however, it is important to understand its full antimicrobial activity to possibly prevent potential complications and secondary infections. </Pgraph><Pgraph>This study examined the antiviral and antimicrobial action of sugar-free CPC/benzocaine lozenges. Both the coronavirus and influenza virus are common causes of pharyngitis, and various institutes monitor the infection rates of these viruses <TextLink reference="27"></TextLink>. Additionally, the possibility of co-infections with these viruses could impact disease severity <TextLink reference="28"></TextLink>, <TextLink reference="29"></TextLink>. Therefore, these two viruses were included in this study. The findings of this in vitro study confirmed a virucidal efficacy of sugar-free CPC/benzocaine lozenges on the enveloped viruses bovine coronavirus and influenza virus. According to the European standard employed, a reduction of viral infectivity by ≥4 lg levels is regarded as virucidal activity <TextLink reference="22"></TextLink>. The sugar-free lozenge demonstrated virucidal activity consistent with the time a lozenge remains in the mouth (within a mean±standard deviation of 6.77±2.01 min) <TextLink reference="9"></TextLink>: at 10 min with the bovine coronavirus for both interfering substances; with influenza virus, at 10 min onwards using the tripartite soil load and at 5 min onwards using clean conditions. The results observed for influenza virus H1N1 and bovine coronavirus could be transferable to other influenza viruses and to human variants of coronavirus, respectively <TextLink reference="30"></TextLink>, <TextLink reference="31"></TextLink>. </Pgraph><Pgraph>This study used bacterial species present in pharyngitis with a broad range of cell structures and sensitivities, including gram-negative anaerobes (<Mark2>P. intermedia, </Mark2><TextGroup><Mark2>P. g</Mark2></TextGroup><Mark2>ingivalis</Mark2>), gram-positive cocci (<Mark2>S. pyogenes, S. pneumoniae, S. dysgalactiae, S. aureus</Mark2>), and bacilli <Mark2>(A. haemolyticum</Mark2>), as well as gram-negative cocci (<Mark2>M. catarrhalis</Mark2>) and bacilli (<Mark2>P. aeruginosa, E. coli</Mark2>) <TextLink reference="8"></TextLink>, <TextLink reference="32"></TextLink>, <TextLink reference="33"></TextLink>. <TextGroup><Mark2>S. py</Mark2></TextGroup><Mark2>ogenes</Mark2> was of particular interest because it is the most frequent cause of bacterial pharyngitis <TextLink reference="8"></TextLink>, <TextLink reference="9"></TextLink>. Additionally, <Mark2>M. catarrhalis</Mark2> is often found in conjunction with <TextGroup><Mark2>S. p</Mark2></TextGroup><Mark2>yogenes</Mark2> in patients with certain types of pharyngitis (e.g., tonsillopharyngitis) and has been shown to enhance the adhesion of <Mark2>S. pyogenes</Mark2> to the nasopharyngeal epithelium <TextLink reference="34"></TextLink>, <TextLink reference="35"></TextLink>, <TextLink reference="36"></TextLink>. Although <TextGroup><Mark2>E. coli</Mark2></TextGroup> does not typically cause pharyngitis, it was included because of its known connection with antimicrobial resistance <TextLink reference="37"></TextLink>. In addition, the study also included <Mark2>C. albi</Mark2><Mark2></Mark2><TextGroup><Mark2>ca</Mark2></TextGroup><Mark2>ns</Mark2>, a yeast that can cause acute pharyngitis <TextLink reference="38"></TextLink>. Currently, there are limited data on the efficacy of sugar-free antiseptic/anesthetic lozenges. However, this study showed that sugar-free CPC/benzocaine lozenge demonstrated bactericidal activity against all challenge microorganisms, and results were consistent with the time a lozenge takes to dissolve in the mouth; within <TextGroup><PlainText>5 m</PlainText></TextGroup>in <TextLink reference="9"></TextLink>, nine of the challenge microorganisms (<Mark2>P. aeruginosa, S. aureus, A. haemolyticum, M. catarrhalis, </Mark2><TextGroup><Mark2>P. g</Mark2></TextGroup><Mark2>ingivalis, P. intermedia, S. dysgalactiae, S. pneumoniae</Mark2>, and <Mark2>S. pyogenes</Mark2>) achieved a plate count of <TextGroup><PlainText><10 C</PlainText></TextGroup>FU/mL. Within 30 min, all of the challenge microorganisms achieved a plate count of <10 CFU/mL. </Pgraph><Pgraph>Having a lozenge with antiviral and antibacterial properties is important; for instance, influenza virus is activated by furin protease from bacteria, so influenza virus is more infectious if bacteria are present <TextLink reference="39"></TextLink>. However, often only antibiotics are prescribed, which does not treat the viral infection <TextLink reference="7"></TextLink>, <TextLink reference="15"></TextLink>. This common misuse can significantly contribute to antimicrobial resistance <TextLink reference="7"></TextLink>, <TextLink reference="12"></TextLink>. Therefore, it is important to use products with both antiviral and antibacterial properties to help avoid unnecessary prescription of antibiotics, and hence reduce antimicrobial resistance <TextLink reference="9"></TextLink>.</Pgraph></TextBlock>
<TextBlock name="Limitations" linked="yes">
<MainHeadline>Limitations</MainHeadline><Pgraph>Firstly, only in vitro testing was performed, which does not fully reflect the throat environment and cannot precisely replicate how the lozenges would act in a patient’s throat. For example, the study only focused on planktonic bacteria in isolation; however, the throat may contain a greater range of bacteria. </Pgraph><Pgraph>In addition, the in vitro method cannot determine the effect of biofilms within the oropharyngeal space, or the effect of the immune system on antimicrobial activity; generating biofilm data and in vivo testing would be an interesting next step. </Pgraph><Pgraph>However, the in vitro method allows rapid generation of robust data for numerous microorganisms simultaneously. The in vitro/in vivo correlation is a biopredictive mathematical model that can help establish a relationship between in vitro and in vivo efficacy <TextLink reference="18"></TextLink>. Therefore, in vitro data could also be used to potentially predict lozenge efficacy in vivo.</Pgraph></TextBlock>
<TextBlock name="Conclusions" linked="yes">
<MainHeadline>Conclusions</MainHeadline><Pgraph>Sugar-free CPC/benzocaine lozenges demonstrated bactericidal activity against all challenge microorganisms, as well as antifungal activity against <Mark2>C. albicans</Mark2>, with the possibility of viral load reduction in the throat. Results were consistent with the time a lozenge takes to dissolve in the mouth. Thus, sugar-free CPC/benzocaine lozenges can be recommended as an effective OTC option for patients with uncomplicated pharyngitis, offering rapid antimicrobial and antiviral effects. </Pgraph><Pgraph>It is important to note that inclusion of the topical anesthetic benzocaine means these lozenges also provide effective pain relief <TextLink reference="18"></TextLink>, <TextLink reference="40"></TextLink>. In contrast, antibiotics do not provide immediate symptomatic relief, nor are they active against the common viral infections, and inappropriate prescription practices will lead to antimicrobial resistance <TextLink reference="11"></TextLink>. </Pgraph><Pgraph>This study provides robust data to demonstrate antiviral, antibacterial and anesthetic effects of CPC/benzocaine lozenges, showing that they are an effective treatment for self-management of self-limiting upper respiratory tract infections. CPC/benzocaine lozenges could also reduce antibiotic prescribing for self-limiting viral pharyngitis and help reduce antimicrobial resistance.</Pgraph></TextBlock>
<TextBlock name="Notes" linked="yes">
<MainHeadline>Notes</MainHeadline><SubHeadline>Authors’ ORCIDs </SubHeadline><Pgraph><UnorderedList><ListItem level="1">Tina Peiter: <Hyperlink href="https://orcid.org/0009-0009-3056-6180">0009-0009-3056-6180</Hyperlink></ListItem><ListItem level="1">Fergus de Grey-Warter: <Hyperlink href="https://orcid.org/0009-0005-6494-8161">0009-0005-6494-8161</Hyperlink></ListItem><ListItem level="1">Maren Eggers: <Hyperlink href="https://orcid.org/0000-0001-8485-9485">0000-0001-8485-9485</Hyperlink></ListItem><ListItem level="1">Derek Matthews: <Hyperlink href="https://orcid.org/0000-0002-5898-1417">0000-0002-5898-1417</Hyperlink></ListItem></UnorderedList></Pgraph><SubHeadline>Funding</SubHeadline><Pgraph>This manuscript was provided by Reckitt Benckiser Healthcare International Ltd, UK. </Pgraph><SubHeadline>Acknowledgments</SubHeadline><Pgraph>Medical writing assistance was provided by Isabella Janowski of Elements Communications Ltd., London, UK and was funded by Reckitt Benckiser Healthcare International Ltd, UK. No other sources of support have been involved in the development of the manuscript. </Pgraph><SubHeadline>Competing interests</SubHeadline><Pgraph>Maren Eggers is a paid medical consultant for Reckitt Benckiser Deutschland GmbH, Heidelberg, Germany. Derek Matthews, Thomas Hallett and Fergus de Grey-Warter are employees of Reckitt Benckiser Healthcare Ltd, UK. Tina Peiter and Tessa Stahl are employees of Reckitt Benckiser Deutschland GmbH, Heidelberg, Germany. </Pgraph></TextBlock>
<References linked="yes">
<Reference refNo="1">
<RefAuthor>World Health Organization</RefAuthor>
<RefTitle></RefTitle>
<RefYear>2023</RefYear>
<RefBookTitle>Influenza (Seasonal)</RefBookTitle>
<RefPage></RefPage>
<RefTotal>World Health Organization. Influenza (Seasonal). 2023 [accessed 2024 Nov]. Available from: https://www.who.int/news-room/fact-sheets/detail/influenza-(seasonal)</RefTotal>
<RefLink>https://www.who.int/news-room/fact-sheets/detail/influenza-(seasonal)</RefLink>
</Reference>
<Reference refNo="2">
<RefAuthor>Centers for Disease Control and Prevention</RefAuthor>
<RefTitle></RefTitle>
<RefYear>2022</RefYear>
<RefBookTitle>Flu Season</RefBookTitle>
<RefPage></RefPage>
<RefTotal>Centers for Disease Control and Prevention. Flu Season. 2022 [accessed 2024 Nov]. Available from: https://www.cdc.gov/flu/about/season.html</RefTotal>
<RefLink>https://www.cdc.gov/flu/about/season.html</RefLink>
</Reference>
<Reference refNo="3">
<RefAuthor>Lee SS</RefAuthor>
<RefAuthor>Viboud C</RefAuthor>
<RefAuthor>Petersen E</RefAuthor>
<RefTitle>Understanding the rebound of influenza in the post COVID-19 pandemic period holds important clues for epidemiology and control</RefTitle>
<RefYear>2022</RefYear>
<RefJournal>Int J Infect Dis</RefJournal>
<RefPage>1002-4</RefPage>
<RefTotal>Lee SS, Viboud C, Petersen E. Understanding the rebound of influenza in the post COVID-19 pandemic period holds important clues for epidemiology and control. Int J Infect Dis. 2022 Sep;122:1002-4. DOI: 10.1016/j.ijid.2022.08.002</RefTotal>
<RefLink>https://doi.org/10.1016/j.ijid.2022.08.002</RefLink>
</Reference>
<Reference refNo="4">
<RefAuthor>Jin X</RefAuthor>
<RefAuthor>Ren J</RefAuthor>
<RefAuthor>Li R</RefAuthor>
<RefAuthor>Gao Y</RefAuthor>
<RefAuthor>Zhang H</RefAuthor>
<RefAuthor>Li J</RefAuthor>
<RefAuthor>Zhang J</RefAuthor>
<RefAuthor>Wang X</RefAuthor>
<RefAuthor>Wang G</RefAuthor>
<RefTitle>Global burden of upper respiratory infections in 204 countries and territories, from 1990 to 2019</RefTitle>
<RefYear>2021</RefYear>
<RefJournal>EClinicalMedicine</RefJournal>
<RefPage>100986</RefPage>
<RefTotal>Jin X, Ren J, Li R, Gao Y, Zhang H, Li J, Zhang J, Wang X, Wang G. Global burden of upper respiratory infections in 204 countries and territories, from 1990 to 2019. EClinicalMedicine. 2021 Jun 28;37:100986. DOI: 10.1016/j.eclinm.2021.100986</RefTotal>
<RefLink>https://doi.org/10.1016/j.eclinm.2021.100986</RefLink>
</Reference>
<Reference refNo="5">
<RefAuthor>Coutinho G</RefAuthor>
<RefAuthor>Duerden M</RefAuthor>
<RefAuthor>Sessa A</RefAuthor>
<RefAuthor>Caretta-Barradas S</RefAuthor>
<RefAuthor>Altiner A</RefAuthor>
<RefTitle>Worldwide comparison of treatment guidelines for sore throat</RefTitle>
<RefYear>2021</RefYear>
<RefJournal>Int J Clin Pract</RefJournal>
<RefPage>e13879</RefPage>
<RefTotal>Coutinho G, Duerden M, Sessa A, Caretta-Barradas S, Altiner A. Worldwide comparison of treatment guidelines for sore throat. Int J Clin Pract. 2021;75(5):e13879. DOI: 10.1111/ijcp.13879</RefTotal>
<RefLink>https://doi.org/10.1111/ijcp.13879</RefLink>
</Reference>
<Reference refNo="6">
<RefAuthor>Krüger K</RefAuthor>
<RefAuthor>Töpfner N</RefAuthor>
<RefAuthor>Berner R</RefAuthor>
<RefAuthor>Windfuhr J</RefAuthor>
<RefAuthor>Oltrogge JH</RefAuthor>
<RefAuthor> Guideline group</RefAuthor>
<RefTitle>Clinical Practice Guideline: Sore Throat</RefTitle>
<RefYear>2021</RefYear>
<RefJournal>Dtsch Arztebl Int</RefJournal>
<RefPage>188-94</RefPage>
<RefTotal>Krüger K, Töpfner N, Berner R, Windfuhr J, Oltrogge JH; Guideline group. Clinical Practice Guideline: Sore Throat. Dtsch Arztebl Int. 2021 Mar 19;118(11):188-94. DOI: 10.3238/arztebl.m2021.0121</RefTotal>
<RefLink>https://doi.org/10.3238/arztebl.m2021.0121</RefLink>
</Reference>
<Reference refNo="7">
<RefAuthor>Shephard A</RefAuthor>
<RefAuthor>Zybeshari S</RefAuthor>
<RefTitle>Virucidal action of sore throat lozenges against respiratory viruses parainfluenza type 3 and cytomegalovirus</RefTitle>
<RefYear>2015</RefYear>
<RefJournal>Antiviral Res</RefJournal>
<RefPage>158-62</RefPage>
<RefTotal>Shephard A, Zybeshari S. Virucidal action of sore throat lozenges against respiratory viruses parainfluenza type 3 and cytomegalovirus. Antiviral Res. 2015 Nov;123:158-62. DOI: 10.1016/j.antiviral.2015.09.012</RefTotal>
<RefLink>https://doi.org/10.1016/j.antiviral.2015.09.012</RefLink>
</Reference>
<Reference refNo="8">
<RefAuthor>Matthews D</RefAuthor>
<RefAuthor>Atkinson R</RefAuthor>
<RefAuthor>Shephard A</RefAuthor>
<RefTitle>Spectrum of bactericidal action of amylmetacresol/2,4-dichlorobenzyl alcohol lozenges against oropharyngeal organisms implicated in pharyngitis</RefTitle>
<RefYear>2018</RefYear>
<RefJournal>Int J Gen Med</RefJournal>
<RefPage>451-6</RefPage>
<RefTotal>Matthews D, Atkinson R, Shephard A. Spectrum of bactericidal action of amylmetacresol/2,4-dichlorobenzyl alcohol lozenges against oropharyngeal organisms implicated in pharyngitis. Int J Gen Med. 2018 Nov 28;11:451-6. DOI: 10.2147/IJGM.S184406</RefTotal>
<RefLink>https://doi.org/10.2147/IJGM.S184406</RefLink>
</Reference>
<Reference refNo="9">
<RefAuthor>Matthews D</RefAuthor>
<RefAuthor>Adegoke O</RefAuthor>
<RefAuthor>Shephard A</RefAuthor>
<RefTitle>Bactericidal activity of hexylresorcinol lozenges against oropharyngeal organisms associated with acute sore throat</RefTitle>
<RefYear>2020</RefYear>
<RefJournal>BMC Res Notes</RefJournal>
<RefPage>99</RefPage>
<RefTotal>Matthews D, Adegoke O, Shephard A. Bactericidal activity of hexylresorcinol lozenges against oropharyngeal organisms associated with acute sore throat. BMC Res Notes. 2020 Feb 24;13(1):99. DOI: 10.1186/s13104-020-04954-1</RefTotal>
<RefLink>https://doi.org/10.1186/s13104-020-04954-1</RefLink>
</Reference>
<Reference refNo="10">
<RefAuthor>Steyer A</RefAuthor>
<RefAuthor>Marušić M</RefAuthor>
<RefAuthor>Kolenc M</RefAuthor>
<RefAuthor>Triglav T</RefAuthor>
<RefTitle>A throat lozenge with fixed combination of cetylpyridinium chloride and benzydamine hydrochloride has direct virucidal effect on SARS-CoV-2</RefTitle>
<RefYear>2021</RefYear>
<RefJournal>COVID</RefJournal>
<RefPage>435-46</RefPage>
<RefTotal>Steyer A, Marušić M, Kolenc M, Triglav T. A throat lozenge with fixed combination of cetylpyridinium chloride and benzydamine hydrochloride has direct virucidal effect on SARS-CoV-2. COVID. 2021;1(2):435-46. DOI: 10.3390/covid1020037</RefTotal>
<RefLink>https://doi.org/10.3390/covid1020037</RefLink>
</Reference>
<Reference refNo="11">
<RefAuthor>Schachtel B</RefAuthor>
<RefAuthor>Shephard A</RefAuthor>
<RefAuthor>Schachtel E</RefAuthor>
<RefAuthor>Shea T</RefAuthor>
<RefAuthor>Smith A</RefAuthor>
<RefAuthor>Tselenti E</RefAuthor>
<RefTitle>Evidence of the Efficacy of Flurbiprofen 8.75 mg Lozenges for Patients Receiving Antibiotics for Laboratory-Confirmed Streptococcal Pharyngitis</RefTitle>
<RefYear>2023</RefYear>
<RefJournal>Ear Nose Throat J</RefJournal>
<RefPage>NP609-NP617</RefPage>
<RefTotal>Schachtel B, Shephard A, Schachtel E, Shea T, Smith A, Tselenti E. Evidence of the Efficacy of Flurbiprofen 8.75 mg Lozenges for Patients Receiving Antibiotics for Laboratory-Confirmed Streptococcal Pharyngitis. Ear Nose Throat J. 2023 Dec;102(12):NP609-NP617. DOI: 10.1177/01455613211025754</RefTotal>
<RefLink>https://doi.org/10.1177/01455613211025754</RefLink>
</Reference>
<Reference refNo="12">
<RefAuthor>World Health Organization</RefAuthor>
<RefTitle></RefTitle>
<RefYear>2023</RefYear>
<RefBookTitle>Antimicrobial resistance</RefBookTitle>
<RefPage></RefPage>
<RefTotal>World Health Organization. Antimicrobial resistance. 2023 [accessed 2024 Nov]. Available from: https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance</RefTotal>
<RefLink>https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance</RefLink>
</Reference>
<Reference refNo="13">
<RefAuthor>Ray P</RefAuthor>
<RefAuthor>Singh S</RefAuthor>
<RefAuthor>Gupta S</RefAuthor>
<RefTitle>Topical antimicrobial therapy: Current status and challenges</RefTitle>
<RefYear>2019</RefYear>
<RefJournal>Indian J Med Microbiol</RefJournal>
<RefPage>299-308</RefPage>
<RefTotal>Ray P, Singh S, Gupta S. Topical antimicrobial therapy: Current status and challenges. Indian J Med Microbiol. 2019 Jul-Sep;37(3):299-308. DOI: 10.4103/ijmm.IJMM_19_443</RefTotal>
<RefLink>https://doi.org/10.4103/ijmm.IJMM_19_443</RefLink>
</Reference>
<Reference refNo="14">
<RefAuthor>Huebner ON</RefAuthor>
<RefAuthor>Assadian O</RefAuthor>
<RefAuthor>Harfenstein I</RefAuthor>
<RefAuthor>Moesges R</RefAuthor>
<RefAuthor>Koburger T</RefAuthor>
<RefAuthor>Weber U</RefAuthor>
<RefAuthor></RefAuthor>
<RefTitle>Microbiological Efficacy of Throat Antiseptics Used as A Spray or A Solution in Healthy Volunteers</RefTitle>
<RefYear>2008</RefYear>
<RefJournal>Anti-Infective Agents in Medicinal Chemistry</RefJournal>
<RefPage>281-4</RefPage>
<RefTotal>Huebner ON, Assadian O, Harfenstein I, Moesges R, Koburger T, Weber U, et al. Microbiological Efficacy of Throat Antiseptics Used as A Spray or A Solution in Healthy Volunteers. Anti-Infective Agents in Medicinal Chemistry. 2008;7(4):281-4. DOI: 10.2174/187152108785908857</RefTotal>
<RefLink>https://doi.org/10.2174/187152108785908857</RefLink>
</Reference>
<Reference refNo="15">
<RefAuthor>McNally D</RefAuthor>
<RefAuthor>Shephard A</RefAuthor>
<RefAuthor>Field E</RefAuthor>
<RefTitle>Randomised, double-blind, placebo-controlled study of a single dose of an amylmetacresol/2,4-dichlorobenzyl alcohol plus lidocaine lozenge or a hexylresorcinol lozenge for the treatment of acute sore throat due to upper respiratory tract infection</RefTitle>
<RefYear>2012</RefYear>
<RefJournal>J Pharm Pharm Sci</RefJournal>
<RefPage>281-94</RefPage>
<RefTotal>McNally D, Shephard A, Field E. Randomised, double-blind, placebo-controlled study of a single dose of an amylmetacresol/2,4-dichlorobenzyl alcohol plus lidocaine lozenge or a hexylresorcinol lozenge for the treatment of acute sore throat due to upper respiratory tract infection. J Pharm Pharm Sci. 2012;15(2):281-94. DOI: 10.18433/j31309</RefTotal>
<RefLink>https://doi.org/10.18433/j31309</RefLink>
</Reference>
<Reference refNo="16">
<RefAuthor>Michel C</RefAuthor>
<RefAuthor>Salvatico S</RefAuthor>
<RefAuthor>Belkhelfa H</RefAuthor>
<RefAuthor>Haddioui L</RefAuthor>
<RefAuthor>Roques C</RefAuthor>
<RefTitle>Activity of Drill® lozenges on the main microorganisms responsible for upper respiratory tract infections</RefTitle>
<RefYear>2013</RefYear>
<RefJournal>Eur Ann Otorhinolaryngol Head Neck Dis</RefJournal>
<RefPage>189-93</RefPage>
<RefTotal>Michel C, Salvatico S, Belkhelfa H, Haddioui L, Roques C. Activity of Drill® lozenges on the main microorganisms responsible for upper respiratory tract infections. Eur Ann Otorhinolaryngol Head Neck Dis. 2013 Sep;130(4):189-93. DOI: 10.1016/j.anorl.2012.09.009</RefTotal>
<RefLink>https://doi.org/10.1016/j.anorl.2012.09.009</RefLink>
</Reference>
<Reference refNo="17">
<RefAuthor>Donath F</RefAuthor>
<RefAuthor>Mallefet P</RefAuthor>
<RefAuthor>Garreffa S</RefAuthor>
<RefAuthor>Furcha R</RefAuthor>
<RefTitle>Efficacy of 8 mg lidocaine and 2? mg cetylpyridinium chloride (CPC) fixed-combination lozenges on sore throat pain intensity compared with 1 mg lidocaine and 2 mg CPC fixed-combination lozenges in subjects with sore throat due to upper respiratory tract infection: a randomized double-blind parallel-group single-dose study</RefTitle>
<RefYear>2018</RefYear>
<RefJournal>Trials</RefJournal>
<RefPage>679</RefPage>
<RefTotal>Donath F, Mallefet P, Garreffa S, Furcha R. Efficacy of 8 mg lidocaine and 2 ?mg cetylpyridinium chloride (CPC) fixed-combination lozenges on sore throat pain intensity compared with 1 mg lidocaine and 2 mg CPC fixed-combination lozenges in subjects with sore throat due to upper respiratory tract infection: a randomized double-blind parallel-group single-dose study. Trials. 2018 Dec 12;19(1):679. DOI: 10.1186/s13063-018-3077-6</RefTotal>
<RefLink>https://doi.org/10.1186/s13063-018-3077-6</RefLink>
</Reference>
<Reference refNo="18">
<RefAuthor>Cardot JM</RefAuthor>
<RefAuthor>Savania N</RefAuthor>
<RefAuthor>Targett D</RefAuthor>
<RefAuthor>Freeman B</RefAuthor>
<RefAuthor>Gray H</RefAuthor>
<RefAuthor>Stahl T</RefAuthor>
<RefAuthor>Kästner U</RefAuthor>
<RefAuthor>Kulasekaran A</RefAuthor>
<RefTitle>Validated correlation of mass loss and drug release in vitro and in healthy subjects for sugared and sugar-free cetylpyridinium chloride (CPC) and benzocaine (1.4 mg/10 mg) lozenges supports in vitro mass loss and corresponding drug release as a surrogate for local bioequivalence</RefTitle>
<RefYear>2022</RefYear>
<RefJournal>J Drug Deliv Sci Technol</RefJournal>
<RefPage>103822</RefPage>
<RefTotal>Cardot JM, Savania N, Targett D, Freeman B, Gray H, Stahl T, Kästner U, Kulasekaran A. Validated correlation of mass loss and drug release in vitro and in healthy subjects for sugared and sugar-free cetylpyridinium chloride (CPC) and benzocaine (1.4 mg/10 mg) lozenges supports in vitro mass loss and corresponding drug release as a surrogate for local bioequivalence. J Drug Deliv Sci Technol. 2022;77:103822. DOI: 10.1016/j.jddst.2022.103822</RefTotal>
<RefLink>https://doi.org/10.1016/j.jddst.2022.103822</RefLink>
</Reference>
<Reference refNo="19">
<RefAuthor>Pitten FA</RefAuthor>
<RefAuthor>Kramer A</RefAuthor>
<RefTitle>Efficacy of cetylpyridinium chloride used as oropharyngeal antiseptic</RefTitle>
<RefYear>2001</RefYear>
<RefJournal>Arzneimittelforschung</RefJournal>
<RefPage>588-95</RefPage>
<RefTotal>Pitten FA, Kramer A. Efficacy of cetylpyridinium chloride used as oropharyngeal antiseptic. Arzneimittelforschung. 2001;51(7):588-95. DOI: 10.1055/s-0031-1300084</RefTotal>
<RefLink>https://doi.org/10.1055/s-0031-1300084</RefLink>
</Reference>
<Reference refNo="20">
<RefAuthor>Popkin DL</RefAuthor>
<RefAuthor>Zilka S</RefAuthor>
<RefAuthor>Dimaano M</RefAuthor>
<RefAuthor>Fujioka H</RefAuthor>
<RefAuthor>Rackley C</RefAuthor>
<RefAuthor>Salata R</RefAuthor>
<RefAuthor>Griffith A</RefAuthor>
<RefAuthor>Mukherjee PK</RefAuthor>
<RefAuthor>Ghannoum MA</RefAuthor>
<RefAuthor>Esper F</RefAuthor>
<RefTitle>Cetylpyridinium Chloride (CPC) Exhibits Potent, Rapid Activity Against Influenza Viruses in vitro and in vivo</RefTitle>
<RefYear>2017</RefYear>
<RefJournal>Pathog Immun</RefJournal>
<RefPage>252-69</RefPage>
<RefTotal>Popkin DL, Zilka S, Dimaano M, Fujioka H, Rackley C, Salata R, Griffith A, Mukherjee PK, Ghannoum MA, Esper F. Cetylpyridinium Chloride (CPC) Exhibits Potent, Rapid Activity Against Influenza Viruses in vitro and in vivo. Pathog Immun. 2017;2(2):252-69. DOI: 10.20411/pai.v2i2.200</RefTotal>
<RefLink>https://doi.org/10.20411/pai.v2i2.200</RefLink>
</Reference>
<Reference refNo="21">
<RefAuthor>Lachenmeier DW</RefAuthor>
<RefTitle>Antiseptic drugs and disinfectants with special scrutiny of COVID-19 pandemic related side effects</RefTitle>
<RefYear>2021</RefYear>
<RefJournal>Side Effects of Drugs Annual</RefJournal>
<RefPage>275-84</RefPage>
<RefTotal>Lachenmeier DW. Antiseptic drugs and disinfectants with special scrutiny of COVID-19 pandemic related side effects. Side Effects of Drugs Annual. 2021;43:275-84. DOI: 10.1016/bs.seda.2021.03.001</RefTotal>
<RefLink>https://doi.org/10.1016/bs.seda.2021.03.001</RefLink>
</Reference>
<Reference refNo="22">
<RefAuthor>Eggers M</RefAuthor>
<RefAuthor>Schwebke I</RefAuthor>
<RefAuthor>Suchomel M</RefAuthor>
<RefAuthor>Fotheringham V</RefAuthor>
<RefAuthor>Gebel J</RefAuthor>
<RefAuthor>Meyer B</RefAuthor>
<RefAuthor>Morace G</RefAuthor>
<RefAuthor>Roedger HJ</RefAuthor>
<RefAuthor>Roques C</RefAuthor>
<RefAuthor>Visa P</RefAuthor>
<RefAuthor>Steinhauer K</RefAuthor>
<RefTitle>The European tiered approach for virucidal efficacy testing - rationale for rapidly selecting disinfectants against emerging and re-emerging viral diseases</RefTitle>
<RefYear>2021</RefYear>
<RefJournal>Euro Surveill</RefJournal>
<RefPage>2000708</RefPage>
<RefTotal>Eggers M, Schwebke I, Suchomel M, Fotheringham V, Gebel J, Meyer B, Morace G, Roedger HJ, Roques C, Visa P, Steinhauer K. The European tiered approach for virucidal efficacy testing - rationale for rapidly selecting disinfectants against emerging and re-emerging viral diseases. Euro Surveill. 2021 Jan;26(3):2000708. DOI: 10.2807/1560-7917.ES.2021.26.3.2000708</RefTotal>
<RefLink>https://doi.org/10.2807/1560-7917.ES.2021.26.3.2000708</RefLink>
</Reference>
<Reference refNo="23">
<RefAuthor>Beadling C</RefAuthor>
<RefAuthor>Slifka MK</RefAuthor>
<RefTitle>How do viral infections predispose patients to bacterial infections?</RefTitle>
<RefYear>2004</RefYear>
<RefJournal>Curr Opin Infect Dis</RefJournal>
<RefPage>185-91</RefPage>
<RefTotal>Beadling C, Slifka MK. How do viral infections predispose patients to bacterial infections? Curr Opin Infect Dis. 2004 Jun;17(3):185-91. DOI: 10.1097/00001432-200406000-00003</RefTotal>
<RefLink>https://doi.org/10.1097/00001432-200406000-00003</RefLink>
</Reference>
<Reference refNo="24">
<RefAuthor>Liu Y</RefAuthor>
<RefAuthor>Ling L</RefAuthor>
<RefAuthor>Wong SH</RefAuthor>
<RefAuthor>Wang MH</RefAuthor>
<RefAuthor>Fitzgerald JR</RefAuthor>
<RefAuthor>Zou X</RefAuthor>
<RefAuthor>Fang S</RefAuthor>
<RefAuthor>Liu X</RefAuthor>
<RefAuthor>Wang X</RefAuthor>
<RefAuthor>Hu W</RefAuthor>
<RefAuthor>Chan H</RefAuthor>
<RefAuthor>Wang Y</RefAuthor>
<RefAuthor>Huang D</RefAuthor>
<RefAuthor>Li Q</RefAuthor>
<RefAuthor>Wong WT</RefAuthor>
<RefAuthor>Choi G</RefAuthor>
<RefAuthor>Zou H</RefAuthor>
<RefAuthor>Hui DS</RefAuthor>
<RefAuthor>Yu J</RefAuthor>
<RefAuthor>Tse G</RefAuthor>
<RefAuthor>Gin T</RefAuthor>
<RefAuthor>Wu WK</RefAuthor>
<RefAuthor>Chan MT</RefAuthor>
<RefAuthor>Zhang L</RefAuthor>
<RefTitle>Outcomes of respiratory viral-bacterial co-infection in adult hospitalized patients</RefTitle>
<RefYear>2021</RefYear>
<RefJournal>EClinicalMedicine</RefJournal>
<RefPage>100955</RefPage>
<RefTotal>Liu Y, Ling L, Wong SH, Wang MH, Fitzgerald JR, Zou X, Fang S, Liu X, Wang X, Hu W, Chan H, Wang Y, Huang D, Li Q, Wong WT, Choi G, Zou H, Hui DS, Yu J, Tse G, Gin T, Wu WK, Chan MT, Zhang L. Outcomes of respiratory viral-bacterial co-infection in adult hospitalized patients. EClinicalMedicine. 2021 Jun 10;37:100955. DOI: 10.1016/j.eclinm.2021.100955</RefTotal>
<RefLink>https://doi.org/10.1016/j.eclinm.2021.100955</RefLink>
</Reference>
<Reference refNo="25">
<RefAuthor>Francis NA</RefAuthor>
<RefAuthor>Butler CC</RefAuthor>
<RefTitle>Chapter 44 – Infections of the upper respiratory tract</RefTitle>
<RefYear>2010</RefYear>
<RefBookTitle>Antibiotic and Chemotherapy (Ninth Edition)</RefBookTitle>
<RefPage>567-73</RefPage>
<RefTotal>Francis NA, Butler CC. Chapter 44 – Infections of the upper respiratory tract. In: Finch RG, Greenwood D, Norrby SR, Whitley RJ, editors. Antibiotic and Chemotherapy (Ninth Edition). London: W.B. Saunders; 2010. pp. 567-73.</RefTotal>
</Reference>
<Reference refNo="26">
<RefAuthor>Eccles R</RefAuthor>
<RefTitle>4.33 - Cough and common cold</RefTitle>
<RefYear>2022</RefYear>
<RefBookTitle>Comprehensive Pharmacology</RefBookTitle>
<RefPage>745-61</RefPage>
<RefTotal>Eccles R. 4.33 - Cough and common cold. In: Kenakin T, editor. Comprehensive Pharmacology. Oxford: Elsevier; 2022. pp. 745-61.</RefTotal>
</Reference>
<Reference refNo="27">
<RefAuthor>Arnold JC</RefAuthor>
<RefAuthor>Nizet V</RefAuthor>
<RefTitle>Pharyngitis</RefTitle>
<RefYear>2018</RefYear>
<RefJournal>Principles and Practice of Pediatric Infectious Diseases</RefJournal>
<RefPage>202-8</RefPage>
<RefTotal>Arnold JC, Nizet V. Pharyngitis. Principles and Practice of Pediatric Infectious Diseases. 2018:202-8.e2. DOI: 10.1016/b978-0-323-40181-4.00027-x</RefTotal>
<RefLink>https://doi.org/10.1016/b978-0-323-40181-4.00027-x</RefLink>
</Reference>
<Reference refNo="28">
<RefAuthor>Feldman C</RefAuthor>
<RefAuthor>Anderson R</RefAuthor>
<RefTitle>The role of co-infections and secondary infections in patients with COVID-19</RefTitle>
<RefYear>2021</RefYear>
<RefJournal>Pneumonia (Nathan)</RefJournal>
<RefPage>5</RefPage>
<RefTotal>Feldman C, Anderson R. The role of co-infections and secondary infections in patients with COVID-19. Pneumonia (Nathan). 2021 Apr 25;13(1):5. DOI: 10.1186/s41479-021-00083-w</RefTotal>
<RefLink>https://doi.org/10.1186/s41479-021-00083-w</RefLink>
</Reference>
<Reference refNo="29">
<RefAuthor>Jia L</RefAuthor>
<RefAuthor>Xie J</RefAuthor>
<RefAuthor>Zhao J</RefAuthor>
<RefAuthor>Cao D</RefAuthor>
<RefAuthor>Liang Y</RefAuthor>
<RefAuthor>Hou X</RefAuthor>
<RefAuthor>Wang L</RefAuthor>
<RefAuthor>Li Z</RefAuthor>
<RefTitle>Mechanisms of Severe Mortality-Associated Bacterial Co-infections Following Influenza Virus Infection</RefTitle>
<RefYear>2017</RefYear>
<RefJournal>Front Cell Infect Microbiol</RefJournal>
<RefPage>338</RefPage>
<RefTotal>Jia L, Xie J, Zhao J, Cao D, Liang Y, Hou X, Wang L, Li Z. Mechanisms of Severe Mortality-Associated Bacterial Co-infections Following Influenza Virus Infection. Front Cell Infect Microbiol. 2017 Aug 3;7:338. DOI: 10.3389/fcimb.2017.00338</RefTotal>
<RefLink>https://doi.org/10.3389/fcimb.2017.00338</RefLink>
</Reference>
<Reference refNo="30">
<RefAuthor>Greatorex JS</RefAuthor>
<RefAuthor>Digard P</RefAuthor>
<RefAuthor>Curran MD</RefAuthor>
<RefAuthor>Moynihan R</RefAuthor>
<RefAuthor>Wensley H</RefAuthor>
<RefAuthor>Wreghitt T</RefAuthor>
<RefAuthor>Varsani H</RefAuthor>
<RefAuthor>Garcia F</RefAuthor>
<RefAuthor>Enstone J</RefAuthor>
<RefAuthor>Nguyen-Van-Tam JS</RefAuthor>
<RefTitle>Survival of influenza A(H1N1) on materials found in households: implications for infection control</RefTitle>
<RefYear>2011</RefYear>
<RefJournal>PLoS One</RefJournal>
<RefPage>e27932</RefPage>
<RefTotal>Greatorex JS, Digard P, Curran MD, Moynihan R, Wensley H, Wreghitt T, Varsani H, Garcia F, Enstone J, Nguyen-Van-Tam JS. Survival of influenza A(H1N1) on materials found in households: implications for infection control. PLoS One. 2011;6(11):e27932. DOI: 10.1371/journal.pone.0027932</RefTotal>
<RefLink>https://doi.org/10.1371/journal.pone.0027932</RefLink>
</Reference>
<Reference refNo="31">
<RefAuthor>Steinmann J</RefAuthor>
<RefTitle>Surrogate viruses for testing virucidal efficacy of chemical disinfectants</RefTitle>
<RefYear>2004</RefYear>
<RefJournal>J Hosp Infect</RefJournal>
<RefPage>S49-54</RefPage>
<RefTotal>Steinmann J. Surrogate viruses for testing virucidal efficacy of chemical disinfectants. J Hosp Infect. 2004 Apr;56 Suppl 2:S49-54. DOI: 10.1016/j.jhin.2003.12.030</RefTotal>
<RefLink>https://doi.org/10.1016/j.jhin.2003.12.030</RefLink>
</Reference>
<Reference refNo="32">
<RefAuthor>Bao L</RefAuthor>
<RefAuthor>Peng R</RefAuthor>
<RefAuthor>Ren X</RefAuthor>
<RefAuthor>Ma R</RefAuthor>
<RefAuthor>Li J</RefAuthor>
<RefAuthor>Wang Y</RefAuthor>
<RefTitle>Analysis of some common pathogens and their drug resistance to antibiotics</RefTitle>
<RefYear>2013</RefYear>
<RefJournal>Pak J Med Sci</RefJournal>
<RefPage>135-9</RefPage>
<RefTotal>Bao L, Peng R, Ren X, Ma R, Li J, Wang Y. Analysis of some common pathogens and their drug resistance to antibiotics. Pak J Med Sci. 2013;29(1):135-9. DOI: 10.12669/pjms.291.2744</RefTotal>
<RefLink>https://doi.org/10.12669/pjms.291.2744</RefLink>
</Reference>
<Reference refNo="33">
<RefAuthor>Vollmer W</RefAuthor>
<RefAuthor>Massidda O</RefAuthor>
<RefAuthor>Tomasz A</RefAuthor>
<RefTitle>The Cell Wall of Streptococcus pneumoniae</RefTitle>
<RefYear>2019</RefYear>
<RefJournal>Microbiol Spectr</RefJournal>
<RefPage></RefPage>
<RefTotal>Vollmer W, Massidda O, Tomasz A. The Cell Wall of Streptococcus pneumoniae. Microbiol Spectr. 2019 May;7(3). DOI: 10.1128/microbiolspec.GPP3-0018-2018</RefTotal>
<RefLink>https://doi.org/10.1128/microbiolspec.GPP3-0018-2018</RefLink>
</Reference>
<Reference refNo="34">
<RefAuthor>Gergova RT</RefAuthor>
<RefAuthor>Petrova G</RefAuthor>
<RefAuthor>Gergov S</RefAuthor>
<RefAuthor>Minchev P</RefAuthor>
<RefAuthor>Mitov I</RefAuthor>
<RefAuthor>Strateva T</RefAuthor>
<RefTitle>Microbiological Features of Upper Respiratory Tract Infections in Bulgarian Children for the Period 1998-2014</RefTitle>
<RefYear>2016</RefYear>
<RefJournal>Balkan Med J</RefJournal>
<RefPage>675-80</RefPage>
<RefTotal>Gergova RT, Petrova G, Gergov S, Minchev P, Mitov I, Strateva T. Microbiological Features of Upper Respiratory Tract Infections in Bulgarian Children for the Period 1998-2014. Balkan Med J. 2016 Nov;33(6):675-80. DOI: 10.5152/balkanmedj.2016.150116</RefTotal>
<RefLink>https://doi.org/10.5152/balkanmedj.2016.150116</RefLink>
</Reference>
<Reference refNo="35">
<RefAuthor>Lafontaine ER</RefAuthor>
<RefAuthor>Wall D</RefAuthor>
<RefAuthor>Vanlerberg SL</RefAuthor>
<RefAuthor>Donabedian H</RefAuthor>
<RefAuthor>Sledjeski DD</RefAuthor>
<RefTitle>Moraxella catarrhalis coaggregates with Streptococcus pyogenes and modulates interactions of S. pyogenes with human epithelial cells</RefTitle>
<RefYear>2004</RefYear>
<RefJournal>Infect Immun</RefJournal>
<RefPage>6689-93</RefPage>
<RefTotal>Lafontaine ER, Wall D, Vanlerberg SL, Donabedian H, Sledjeski DD. Moraxella catarrhalis coaggregates with Streptococcus pyogenes and modulates interactions of S. pyogenes with human epithelial cells. Infect Immun. 2004 Nov;72(11):6689-93. DOI: 10.1128/IAI.72.11.6689-6693.2004</RefTotal>
<RefLink>https://doi.org/10.1128/IAI.72.11.6689-6693.2004</RefLink>
</Reference>
<Reference refNo="36">
<RefAuthor>Verhaegh SJ</RefAuthor>
<RefAuthor>Flores AR</RefAuthor>
<RefAuthor>van Belkum A</RefAuthor>
<RefAuthor>Musser JM</RefAuthor>
<RefAuthor>Hays JP</RefAuthor>
<RefTitle>Differential virulence gene expression of group A Streptococcus serotype M3 in response to co-culture with Moraxella catarrhalis</RefTitle>
<RefYear>2013</RefYear>
<RefJournal>PLoS One</RefJournal>
<RefPage>e62549</RefPage>
<RefTotal>Verhaegh SJ, Flores AR, van Belkum A, Musser JM, Hays JP. Differential virulence gene expression of group A Streptococcus serotype M3 in response to co-culture with Moraxella catarrhalis. PLoS One. 2013 Apr 23;8(4):e62549. DOI: 10.1371/journal.pone.0062549</RefTotal>
<RefLink>https://doi.org/10.1371/journal.pone.0062549</RefLink>
</Reference>
<Reference refNo="37">
<RefAuthor>Poirel L</RefAuthor>
<RefAuthor>Madec JY</RefAuthor>
<RefAuthor>Lupo A</RefAuthor>
<RefAuthor>Schink AK</RefAuthor>
<RefAuthor>Kieffer N</RefAuthor>
<RefAuthor>Nordmann P</RefAuthor>
<RefAuthor>Schwarz S</RefAuthor>
<RefTitle>Antimicrobial Resistance in Escherichia coli</RefTitle>
<RefYear>2018</RefYear>
<RefJournal>Microbiol Spectr</RefJournal>
<RefPage></RefPage>
<RefTotal>Poirel L, Madec JY, Lupo A, Schink AK, Kieffer N, Nordmann P, Schwarz S. Antimicrobial Resistance in Escherichia coli. Microbiol Spectr. 2018 Jul;6(4). DOI: 10.1128/microbiolspec.ARBA-0026-2017</RefTotal>
<RefLink>https://doi.org/10.1128/microbiolspec.ARBA-0026-2017</RefLink>
</Reference>
<Reference refNo="38">
<RefAuthor>BMJ</RefAuthor>
<RefTitle></RefTitle>
<RefYear>2023</RefYear>
<RefBookTitle>Acute pharyngitis</RefBookTitle>
<RefPage></RefPage>
<RefTotal>BMJ. Acute pharyngitis. 2023 [accessed 2024 Nov]. Available from: https://bestpractice.bmj.com/topics/en-gb/5</RefTotal>
<RefLink>https://bestpractice.bmj.com/topics/en-gb/5</RefLink>
</Reference>
<Reference refNo="39">
<RefAuthor>Böttcher-Friebertshäuser E</RefAuthor>
<RefAuthor>Klenk HD</RefAuthor>
<RefAuthor>Garten W</RefAuthor>
<RefTitle>Activation of influenza viruses by proteases from host cells and bacteria in the human airway epithelium</RefTitle>
<RefYear>2013</RefYear>
<RefJournal>Pathog Dis</RefJournal>
<RefPage>87-100</RefPage>
<RefTotal>Böttcher-Friebertshäuser E, Klenk HD, Garten W. Activation of influenza viruses by proteases from host cells and bacteria in the human airway epithelium. Pathog Dis. 2013 Nov;69(2):87-100. DOI: 10.1111/2049-632X.12053</RefTotal>
<RefLink>https://doi.org/10.1111/2049-632X.12053</RefLink>
</Reference>
<Reference refNo="40">
<RefAuthor>Chrubasik S</RefAuthor>
<RefAuthor>Beime B</RefAuthor>
<RefAuthor>Magora F</RefAuthor>
<RefTitle>Efficacy of a benzocaine lozenge in the treatment of uncomplicated sore throat</RefTitle>
<RefYear>2012</RefYear>
<RefJournal>Eur Arch Otorhinolaryngol</RefJournal>
<RefPage>571-7</RefPage>
<RefTotal>Chrubasik S, Beime B, Magora F. Efficacy of a benzocaine lozenge in the treatment of uncomplicated sore throat. Eur Arch Otorhinolaryngol. 2012 Feb;269(2):571-7. DOI: 10.1007/s00405-011-1802-9</RefTotal>
<RefLink>https://doi.org/10.1007/s00405-011-1802-9</RefLink>
</Reference>
</References>
<Media>
<Tables>
<Table format="png">
<MediaNo>1</MediaNo>
<MediaID>1</MediaID>
<Caption><Pgraph><Mark1>Table 1: Unique identifier, nutrient agar, and incubation conditions for each test organism (1 mL and 0.5 mL plated)</Mark1></Pgraph></Caption>
</Table>
<Table format="png">
<MediaNo>2</MediaNo>
<MediaID>2</MediaID>
<Caption><Pgraph><Mark1>Table 2: Differences in methods between the method suitability test and the antimicrobial activity test</Mark1></Pgraph></Caption>
</Table>
<Table format="png">
<MediaNo>3</MediaNo>
<MediaID>3</MediaID>
<Caption><Pgraph><Mark1>Table 3: Virucidal effect of CPC/benzocaine sugar-free lozenges against influenza viruses (H1N1)</Mark1></Pgraph></Caption>
</Table>
<Table format="png">
<MediaNo>4</MediaNo>
<MediaID>4</MediaID>
<Caption><Pgraph><Mark1>Table 4: Virucidal effect of CPC/benzocaine sugar-free lozenges against bovine coronavirus</Mark1></Pgraph></Caption>
</Table>
<Table format="png">
<MediaNo>5</MediaNo>
<MediaID>5</MediaID>
<Caption><Pgraph><Mark1>Table 5: Average colony count of each plate over three replicates for all the challenge microorganisms</Mark1><LineBreak></LineBreak><LineBreak></LineBreak></Pgraph></Caption>
</Table>
<NoOfTables>5</NoOfTables>
</Tables>
<Figures>
<NoOfPictures>0</NoOfPictures>
</Figures>
<InlineFigures>
<NoOfPictures>0</NoOfPictures>
</InlineFigures>
<Attachments>
<NoOfAttachments>0</NoOfAttachments>
</Attachments>
</Media>
</OrigData>
</GmsArticle>]]></plaintext></textgroup></pgraph></abstract></origdata></gmsarticle>